Journal of Applied Chemical Science International

Introduction: Fluorine has become a crucial element in modern drug design due to its unique chemical properties that enhance the pharmacokinetic and pharmacodynamic profiles of therapeutic agents. Nearly a quarter of all marketed drugs contain fluorine, which contributes significantly to improved metabolic stability, bioavailability, and target selectivity.

Methods: This review analyzes current synthetic strategies for incorporating fluorine into drug molecules, including electrophilic and nucleophilic fluorination, transition-metal-catalyzed C–H activation, and radical-based approaches. These methodologies enable selective fluorination of aromatic and heteroaromatic compounds, which are central to drug scaffolds. Additionally, we examined case studies of fluorinated drugs across therapeutic areas to evaluate the impact of fluorine on clinical outcomes.

Results: Fluorination enhances drug properties such as metabolic resistance, membrane permeability, and receptor binding affinity. Clinically approved fluorinated drugs show improved efficacy in oncology, central nervous system disorders, infectious diseases, and cardiovascular conditions. The introduction of fluorine also reduces off-target effects and toxicity. Advances in synthetic methods and computational design facilitate the development of diverse fluorinated compounds, while fluorine-labeled PET imaging agents improve diagnostic capabilities.

Conclusion: The strategic incorporation of fluorine remains a powerful approach in drug discovery, contributing to safer and more effective pharmaceuticals. Future research is focused on sustainable fluorination techniques, AI-driven optimization, and expanding therapeutic applications. These efforts will likely accelerate the discovery and approval of next-generation fluorinated drugs.